SEC	Form	4
-----	------	---

FORM 4	4
--------	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

heck this box if no longer subject to ection 16. Form 4 or Form 5 bligations may continue. See	STATEMENT OF CHANGES IN
istruction 1(b).	Filed pursuant to Section 16(a) of the S or Section 30(h) of the Investme

BENEFICIAL OWNERSHIP

Securities Exchange Act of 1934 ent Company Act of 1940

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol FIBROGEN INC FGEN		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Neff Thomas B			FIEROGEN INC [FGEN]	X X	Director Officer (give title below)	Х	10% Owner Other (specify below)		
C/O FIBROGEI	Last) (First) (Middle) C/O FIBROGEN, INC. 409 ILLINOIS ST.		3. Date of Earliest Transaction (Month/Day/Year) 03/04/2015	Chief Executive Officer					
(Street) SAN FRANCISCO	CA	94158	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group F Form filed by One Form filed by More Person	Report	ting Person		
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	03/04/2015		A		73,800 ⁽¹⁾	A	\$0.00	3,916,962	D	
Common Stock								145,070	Ι	By Family Partnership
Common Stock								20,000	Ι	By Spouse
Common Stock								60,176	I	See footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$29.66	03/04/2015		A		147,600		(3)	03/04/2025	Common Stock	147,600	\$0.00	147,600	D	

Explanation of Responses:

1. Represents the grant of restricted stock units that vest over time.

2. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

3. Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in equal amounts quarterly thereafter for the following three years. **Remarks:**

/s/ Dorothy Pacini, Attorney-in-

03/17/2015

** Signature of Reporting Person Date

<u>fact</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.